Navigation Links
Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Date:4/7/2008

" said Edward Lanphier, Sangamo's president and chief executive officer. "There is growing appreciation of the value of our technology as a rapid, reliable and highly specific tool to modify genes in eukaryotic cells and even whole organisms. As this increases we believe that there will be numerous applications of the technology in the generation of a variety of transgenic species as models of human disease and for drug development. "

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
8. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
9. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
10. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
11. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  US-Australian drug discovery company, Novogen Limited ... its comprehensive scientific review has identified high value ... of unmet patient need. Novogen is moving as ... prior to entering into Phase 1 clinical trials ... Chief Executive Officer, Iain Ross , said ...
(Date:8/31/2015)... STOCKHOLM , Aug. 31, 2015 Trimb ... an agreement to acquire YouMedical Group BV ("YouMedical"), a ... YouMedical has total annual sales of approximately EUR 16 ... categories. "Our ambition is to build ... an important step toward that goal. YouMedical gives us ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist ... Annual High Tech Awards. , Now in its 22nd year, this premier awards event ... here, across the nation and around the world. The OC Tech Alliance will announce ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , a ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM ... a focus on evidence-based research and clinical application, the event gathered industry thought ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... pharmaceutical and biotechnology research and development outsourcing company, today ... for the fourth quarter and full year 2010 ended ... host a conference call to discuss the results at ...
... – EMD Serono, Inc., an affiliate of Merck ... a complete response letter (CRL) from the U.S. ... drug application (NDA) for Cladribine Tablets, EMD Serono,s ... therapy for relapsing-remitting multiple sclerosis (MS). ...
... Communications , the team have created a microscope which shatters ... beating the diffraction limit of light. Previously, the standard ... 0.001 millimetres clearly. But now, by combining an ... the Manchester researchers can see 20 times smaller 50 ...
Cached Biology Technology:ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 3EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 4Microscope could 'solve the cause of viruses' 2
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Saudi Arabia Biomedical Sensors market is estimated at $0.23 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... scientists at the Broad Institute of MIT and Harvard announced ... that can connect human diseases with potential drugs to treat ... human cells. Called the "Connectivity Map," the new tool and ... Science and in separate publications in the September 28 immediate ...
... your way through an unfamiliar neighborhood to a friend's ... is adept at adapting. It can make decisions based ... new information. , The nature of such sophisticated decision ... high-level processing, has been "poorly studied and little understood," ...
... sequence of a 5-million-year-old retrovirus and shown that it is ... ancestor of a large family of mobile DNA elements, some ... study, which is the first to generate an infectious retrovirus ... a breakthrough for the field of retrovirus research. The ...
Cached Biology News:Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3Where we change our mind 2Scientists resuscitate a 5 million-year-old retrovirus 2